Carla Talbaux

Chen Katz

David Peckham

Emily Frazier

Isabelle Tihista

Jessica Cross

Kurt Lustig

Mei Xu

Nathan Eyde

Neda Kabi

Remington Lance

Shaarwari Sridhar

Shawn Iadonato

Thierry Guillaudeux

Yulia Ovechkina

Frontiers in Immunology

Directory of Open Access Journals

Frontiers in ImmunologyOPEN ACCESSEDITED AND REVIEWED BYDallas Flies,NextCure, Inc., United States*CORRESPONDENCEThierry Guillaudeuxtguillaudeux@kineta.usRECEIVED 04 January 2024ACCEPTED 16 January 2024PUBLISHED 23 January 2024CITATIONIadonato S, Ovechkina Y, Lustig K, Cross J,Eyde N, Frazier E, Kabi N, Katz C, Lance R,Peckham D, Sridhar S, Talbaux C, Tihista I,Xu M and Guillaudeux T (2024) Corrigendum:A highly potent anti-VISTA antibodyKVA12123 - a new immune checkpointinhibitor and a promising therapy againstpoorly immunogenic tumors.Front. Immunol. 15:1365240.doi: 10.3389/fimmu.2024.1365240COPYRIGHT© 2024 Iadonato, Ovechkina, Lustig, Cross,Eyde, Frazier, Kabi, Katz, Lance, Peckham,Sridhar, Talbaux, Tihista, Xu and Guillaudeux.This is an open-access article distributed underthe terms of the Creative Commons AttributionLicense (CC BY). The use, distribution orreproduction in other forums is permitted,provided the original author(s) and thecopyright owner(s) are credited and that theoriginal publication in this journal is cited, inaccordance with accepted academicpractice. No use, distribution or reproductionis permitted which does not comply withthese terms.TYPE CorrectionPUBLISHED 23 January 2024DOI 10.3389/fimmu.2024.1365240Corrigendum: A highly potentanti-VISTA antibody KVA12123- a new immune checkpointinhibitor and a promisingtherapy against poorlyimmunogenic tumorsShawn Iadonato, Yulia Ovechkina, Kurt Lustig, Jessica Cross,Nathan Eyde, Emily Frazier, Neda Kabi, Chen Katz,Remington Lance, David Peckham, Shaarwari Sridhar,Carla Talbaux, Isabelle Tihista, Mei Xu and Thierry Guillaudeux*Kineta Inc., Seattle, WA, United StatesKEYWORDSVista, PD-1H, B7-H5, immune checkpoint inhibitor, immunotherapy, PD-1 combinationtherapy, poorly immunogenic tumors, tumor microenvironment immunosuppressionA Corrigendum onA highly potent anti-VISTA antibody KVA12123 - a new immune checkpointinhibitor and a promising therapy against poorly immunogenic tumorsby Iadonato S, Ovechkina Y, Lustig K, Cross J, Eyde N, Frazier E, Kabi N, Katz C, Lance R,Peckham D, Sridhar S, Talbaux C, Tihista I, Xu M and Guillaudeux T (2023) Front.Immunol. 14:1311658. doi: 10.3389/fimmu.2023.1311658In the published article, there was an error. More accurate sentences and methods wereprovided in the Abstract and Material and Methods sections to explain the selection of ourfully human monoclonal antibodies.A correction has been made to Abstract, Methods. This sentence previously stated:“Methods: Fully human monoclonal antibodies directed against VISTA were producedafter immunizing humanized Trianni mice and single B cell sequencing. Anti-VISTAantibodies were evaluated for specificity, cross-reactivity, monocyte and T cell activation,Fc-effector functions, and antitumor efficacy using in vitro and in vivo models to select theKVA12123 antibody lead candidate. The pharmacokinetics and safety profiles ofKVA12123 were evaluated in cynomolgus monkeys.”The corrected sentence appears below:“Methods: Fully human monoclonal antibodies directed against VISTA were producedafter immunizing humanized Trianni mice and sorting and sequencing natively-linked Bcell scFv repertoires. Anti-VISTA antibodies were evaluated for specificity, cross-reactivity,monocyte and T cell activation, Fc-effector functions, and antitumor efficacy using in vitroand in vivomodels to select the KVA12123 antibody lead candidate. The pharmacokineticsand safety profiles of KVA12123 were evaluated in cynomolgus monkeys.”frontiersin.org01Iadonato et al. 10.3389/fimmu.2024.1365240A correction has also been made toMaterials and Methods, 2.1Antibody library generation. This sentence previously stated:“2.1 Antibody library generationFully human ScFv antibodies directed against human VISTAwere generated after immunization of humanized Trianni mice andsingle B cell sequencing. Briefly, transgenic humanized Triannimice were immunized with soluble human VISTA extracellulardomain. B cells were isolated from spleen, lymph nodes, and bonemarrow. B cells were then encapsulated into droplets with oligo-dTbeads and a lysis solution to generate a DNA amplicon that encodesthe scFv libraries with native pairing heavy and light Ig. The scFvlibraries were then transfected into yeast cells and stained with thefluorescently labeled soluble VISTA to collect scFv with the highestfluorescent signal. Finally, deep sequencing was used to identify allclones in the pre- and post-sort populations”The corrected sentence appears below:“2.1 Antibody library generationFully human scFv antibodies directed against human VISTAwere generated after immunization of humanized Trianni® miceand sorting natively-linked B cell scFv repertoires. Briefly,transgenic humanized Trianni mice were immunized with solublehuman VISTA-His extracellular domain (R&D Systems). B cellswere isolated from spleen, lymph nodes, and bone marrow. B cellswere then encapsulated into droplets with oligo-dT beads and a lysissolution, followed by overlap-extension RT-PCR to generate a DNAamplicon that encodes the scFv libraries with native pairing heavyand light Ig. The scFv libraries were then transfected into yeast cellsFrontiers in Immunology 02for surface display, stained with biotinylated VISTA-His proteinand Streptavidin-PE conjugate (Life Tech), and scFvs binding toVISTA were sorted by FACS (BD Influx). Finally, deep sequencing(Illumina) was used to identify all clones in the pre- and post-sort populations.”Additionally, in the published article, there was an error in theAcknowledgement statement. The correct Acknowledgementstatement appears below.Acknowledgement StatementVISTA antibody library generation from Trianni mice wasperformed by GigaGen, Inc.; all identified variable sequences werelicensed by Kineta from GigaGen. All other contributions wereassociated with the authors listed in this paper.The authors apologize for these errors and state that they do notchange the scientific conclusions of the article in any way. Theoriginal article has been updated.Publisher’s noteAll claims expressed in this article are solely those of the authorsand do not necessarily represent those of their affiliatedorganizations, or those of the publisher, the editors and thereviewers. Any product that may be evaluated in this article, orclaim that may be made by its manufacturer, is not guaranteed orendorsed by the publisher.frontiersin.org

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1365240/pdf

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals